Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (2)
  • Closed (6)

Medical Condition

  • Show all (271)
  • Autoimmune Disorders (1)
  • Blood Disorders (1)
  • Cancer (78)
    • Bladder Cancer (14)
    • Liver Cancer (1)
    • Lung Cancer (1)
    • Lymphoma (1)
    • Prostate Cancer (1)
    • (-) Solid Tumors (4)
  • COVID-19 (Coronavirus) (1)
  • Ear, Nose and Throat (1)
  • Gastrointestinal and Digestive Diseases (3)
  • Healthy Volunteers (4)
  • Neurological Disorders (174)
    • Alzheimer's Disease (37)
    • Brain Tumors (57)
    • Cerebral Palsy (3)
    • Dementia (8)
    • (-) Huntington's Disease (4)
    • Multiple Sclerosis (8)
    • Neuromuscular (10)
    • Neuropathy (12)
    • Parkinson's Disease (3)
  • Pediatrics (2)
  • Transplant (1)
  • Urology (4)
  • Vascular Conditions (1)
Displaying 1 - 8 of 8

ChANGE HD

Condition: Neurological Disorders / Huntington's Disease
Investigator: Ashwini Rao, EdD, OTR
Status: Currently Recruiting
Child to Adult Neurodevelopment in Gene Expanded Huntingtons Disease (ChANGE HD) HD has long been considered an adult-onset disease. However, research has shown that brain changes are evident before motor symptoms begin. In fact, the gene responsible for HD plays a role in brain development and is present throughout the lifespan. With gene knockdown therapy…
Read More

DfHD - Dance for Huntington's Disease

Condition: Neurological Disorders / Huntington's Disease
Investigator: Ashwini Rao, EdD, OTR
Status: Currently Recruiting
Dance is a complex activity involving the integration of rhythm, spatial patterns, synchronization to external stimuli and whole-body coordination. While regular exercise is often recommended for people with Huntington's Disease (HD), there are no studies examining the use of dance to improve balance and mobility and positively affect the quality of…
Read More

SAGE HD-201

Condition: Neurological Disorders / Huntington's Disease
Investigator: Karen Marder, MD, MPH
Status: Closed
The DIMENSION Study is evaluating the safety and effect on cognitive symptoms of an investigational oral drug in adults with early Huntington's disease. Cognitive symptoms may include difficulty paying attention or trouble thinking through steps of an activity or complex problems. Symptoms may also include difficulty planning, remembering, and staying…
Read More

Tolerability, Safety, and Activity of study drug SRX246 in Irritable Subjects With Huntington's Disease

Condition: Neurological Disorders / Huntington's Disease
Investigator: Karen Marder, MD, MPH
Status: Closed
The purpose of this research study is to find out whether a new investigational drug called SRX246, which might be useful to Huntington's Disease (HD) patients who sometimes feel irritable, angry, or even aggressive, is well tolerated and safe when it is given two times a day by mouth at doses as high as 160 mg. As part of this study, we will use a…
Read More

NKTR-214 in Combination with Pembrolizumab or Atezolizumab in Patients with Advanced or Metastatic Cancer (NSCLC, Bladder, or Melanoma)

Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of NKTR-214 given in combination with KEYTRUDA or TECENTRIQ. We want to find out what effects, good or bad, the study drug has on the body and cancer when combined with KEYTRUDA or TECENTRIQ. The study will recruit participants at least 18…
Read More

Study of XmAb22841 Monotherapy and in Combination with Pembrolizumab in Subjects with Selected Advanced Solid Tumors (DUET-4)

Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab. You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will…
Read More

Study of TSR-042 (anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Read More

Study of Experimental Drug GSK3359609 in Patients with Advanced Solid Tumors

Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
GSK3359609 is a drug that is a type of antibody. It is a kind of immunotherapy that targets the ICOS (anti-Inducible T cell Co-Stimulator) protein present on specific immune cells. ICOS is a cell receptor that enhances the immune response to foreign bodies, and which is expected to help your immune system find and fight cancer cells. It will also be called…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science